IRCT20090117001556N126Not yet recruitingPhase 2
Studying the effect of Adalimumab in the treatment of patients with chronic schizophrenia: A randomized double blind and placebo controlled clinical trial
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •Diagnosis of positive and negative symptoms based on DSM-5
- •Attending hospital with a psychosis attack
- •Age between 18 to 60 years old
Exclusion Criteria
- •Head trauma
- •History of shock therapy during past three months prior to the trial
- •Undergoing neurosurgery
- •Presence of acute or chronic systemic diseases
- •History of allergy to the medication used in this research
- •Receiving any anti-psychotic medications during past eight weeks prior to the trial
Investigators
Similar Trials
Recruiting
Phase 4
Prospective follow-up study of adalimumab treatment in ankylosing spondylitis: efficacy with focus on uveitisAnkylosing spondylitisBechterew's disease10023213NL-OMON30515Vrije Universiteit Medisch Centrum100
Completed
Not Applicable
Prospective study on the effects of adalimumab treatment in patients with rheumatoid arthritisMusculoskeletal DiseasesArthropathiesRheumatoid arthritisISRCTN68762628Academic Medical Center (AMC) (The Netherlands)50
Completed
Phase 3
Therapeutic Effects of Adalimumab in Patients with Resistant PsoriasisIRCT20120524009844N8Tabriz University of Medical Sciences60
Completed
Phase 4
Study of Combination Therapy of Adalimumab and an Immunomodulator for Crohn's Disease(Diamond study)s diseaseCrohn's diseaseJPRN-UMIN000005146Department of Internal Medicine, School of Medicine, Keio University200
Recruiting
Phase 3
Adalimumab effect on COVID-19IRCT20171105037262N4Bagheiat-allah University of Medical Sciences100